Ardelyx’s ambition to revolutionize kidney treatment

A therapy to treat hyperphosphatemia is moving closer to the market after years of development by California-based company Ardelyx. The company’s lead candidate Tenapanor is a targeted, small molecule therapy currently under FDA review.